The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Lapshina A.M.

National Medical Research Center for Endocrinology of the Ministry of Health of Russia

Pigarova E.A.

Endocrinology Research Centre

Abrosimov A.Yu.

National Medical Research Center for Endocrinology of the Ministry of Health of Russia

Algorithm for morphological diagnosis of neoplasms in the chiasmal-sellar region

Authors:

Lapshina A.M., Pigarova E.A., Abrosimov A.Yu.

More about the authors

Read: 3636 times


To cite this article:

Lapshina AM, Pigarova EA, Abrosimov AYu. Algorithm for morphological diagnosis of neoplasms in the chiasmal-sellar region. Russian Journal of Archive of Pathology. 2021;83(6):60‑70. (In Russ.)
https://doi.org/10.17116/patol20218306160

Recommended articles:

References:

  1. Kleinschmidt-DeMasters BK, Lopes MBS, Prayson RA. An Algorithmic Approach to Sellar Region Masses. Arch Pathol Lab Med. 2015;139:356-372.  https://doi.org/10.1007/s12022-017-9498-z
  2. Lopes MBS, Pernicone PJ, Scheithauer BW, Horvath E, Kovacs K. Pituitary and Sellar Region. In: Mills S.E., ed. Histology for Pathologists. 3rd Edition. Charlottesville: Lippincott Williams & Wilkins; 2007;940-1002.
  3. Asa SL. The Normal Pituitary Gland. In: Tumors of the Pituitary Gland. AFIP Atlas of Tumor Pathology Series 4. Washington: American Registry of Pathology; 2011;1-41. 
  4. Jarzembowski J, Lloyd Ri, McKeever P. Type IV Collagen Immunostaining Is a Simple, Reliable Diagnostic Tool for Distinguishing Between Adenomatous and Normal Pituitary Glands. Arch Pathol Lab Med. 2007;131:931-935.  https://doi.org/10.1043/1543-2165(2007)131[931:TICIIA]2.0.CO;2
  5. Mete O, Asa SL. Clinicipathological Correlation in Pituitary Adenomas. Review. Brain Pathology. 2012;22:443-453.  https://doi.org/10.1111/j.1750-3639.2012.00599.x
  6. Asa SL. Practical Pituitary Pathology. What Does the Pathologist Need to Know? Arch Pathol Lab Med. 2008;132:1231-1240. https://doi.org/10.1043/1543-2165(2008)132[1231:PPPWDT]2.0.CO;2
  7. Nose’ V, Ezzat Sh, Horvath E, Kovacs K, Laws ER., Lloyd R, Lopes M BS, Asa SL. Protocol for the Examination of Specimens From Patients With Primary Pituitary Tumors. Arch Pathol Lab Med. 2011;135:640-646.  https://doi.org/10.5858/2010-0470-SAR1.1
  8. Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, Chinezu L, Gardiman P, Lania A, Lapshina AM, Poliani L, Reiniger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Archiv. 2019;475:687-692.  https://doi.org/10.1007/s00428-019-02655-0
  9. Mete O, Lopes MBS. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28:228-243.  https://doi.org/10.1007/s12022-017-9498-z
  10. Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J. Tumours of the pituitary gland. In: WHO Classification of Tumours of Endocrine Organs. IARC Press: Lyon; 2017;11-65. 
  11. Pendharkar AV, Sussman ES, Ho AL, Gephart Melanie GH, Katznelson L. Cushing’s disease: predicting long-term remission after surgical treatment. Neurosurg Focus. 2015;38(2):E13.  https://doi.org/10.3171/2014.10.FOCUS14682
  12. Masanori Yonenaga, Shingo Fujio, Mika Habu, Hiroshi Arimura, Takaaki Hiwatari, Shunichi Tanaka, Yasuyuki Kinoshita, Hiroshi Hosoyama, Hirofumi Hirano, Kazunori Arita. Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria. Neurol Med Chir. 2018;15:58(4):147-155.  https://doi.org/10.2176/nmc.oa.2017-0215
  13. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 2019;33(2):101290. https://doi.org/10.1016/j.beem.2019.101290
  14. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4): 894-904.  https://doi.org/10.1210/jc.2010-1048
  15. Nazato DM, Abucham J. Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center. J Endocrinol Invest. 2018;41(4):447-454.  https://doi.org/10.1007/s40618-017-0770-3
  16. Cebula H, Baussart B, Villa C, Assié G, Boulin A, Foubert L, Aldea S, Bennis S, Bernier M, Proust F, Gaillard S. Efficacy of endoscopic endonasal transsphenoidal surgery for Cushing’s disease in 230 patients with positive and negative MRI. Acta Neurochir. 2017;159:1227-1236. https://doi.org/10.1007/s00701-017-3140-1
  17. Ceylan S, Cabuk B, Koc K, Anik I, Vural C. Acta Neurochir. 2013; 155:1611-1619. https://doi.org/10.1007/s00701-013-1754-5
  18. Oldfield EH, Vortmeyer AO. Development of a histological pseudocapsule and its use as a surgical capsule in the excision of pituitary tumors. J Neurosurg. 2006;104:7-19.  https://doi.org/10.3171/jns.2006.104.1.7
  19. Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab. 2018;104:2473-2489. https://doi.org/10.1210/jc.2018-00688
  20. Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat Sh, Asa SL. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol. 2016;29(2):131-142.  https://doi.org/10.1038/modpathol.2015.151
  21. Gomez-Hernandez K, Ezzat Sh, Asa SL, Mete O. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Turk Patoloji Derg. 2015;31:4-17.  https://doi.org/10.5146/tjpath.2015.01311
  22. Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J, and the attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016 From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24:5-8.  https://doi.org/10.1530/ERC-17-0004
  23. Trouillas J, Roy P, Sturm N et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126:123-135.  https://doi.org/10.1007/s00401-013-1084-y
  24. Asioli S, Righi A, Iommi M, Baldovini C, Ambrosi F, Guaraldi F, Zoli M, Mazzatenta D, Faustini-Fustini M, Rucci P, Giannini C, Foschini MP Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol. 2019;180:127-134.  https://doi.org/10.1530/EJE-18-0749
  25. Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J. Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab. 2017;102: 3368-3374. https://doi.org/10.1210/jc.2017-00773
  26. Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G. Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol. 2018;178:7-9.  https://doi.org/10.1530/EJE-18-0250
  27. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J and M Dekkers O. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:1-24.  https://doi.org/10.1530/EJE-17-0796
  28. Casar-Borota, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide. J Clin Endocrinol Metab. 2013;98(11):1730-1739. https://doi.org/10.1210/jc.2013-2145
  29. Kleinschmidt-DeMasters BK, Lopes MB. Update on hypophysitis and TTF-1 expressing sellar region masses. Brain Pathol. 2013;23(5):495-514.  https://doi.org/10.1111/bpa.12068
  30. Zygourakis CC, Rolston JD, Lee HS., Partow C, Kunwar S, Aghi MK. Pituicytomas and spindle cell oncocytomas: modern case series from the University of California, San Francisco. Pituitary. 2015;18:150-158.  https://doi.org/10.1007/s11102-014-0568-7
  31. Viaene AN, Lee EB, Rosenbaum JN, Nasrallah IM, MacLean PN. Histologic,.mmunohistochemical, and molecular features of pituicytomas and atypical pituicytomas. Acta Neuropathol. 2019;7:69.  https://doi.org/10.1186/s40478-019-0722-6
  32. Javanbakht A, Massimo D’A, Badie B, Salehian B. Pituitary metastasis: a rare condition. Endocrine Connect. 2018;7:1049-1057. https://doi.org/10.1530/EC-18-0338
  33. Dou XL, Zhou N, Mai YL, Guan M, Sun Z, Gao X & Bai CM. Gastric cancer with pituitary metastasis presenting as symptomatic secondary adrenal insufficiency: a case report. Journal of Digest Diseases. 2017;18:369-372.  https://doi.org/10.1111/1751-2980.12476
  34. Feghaly J, Astras G. Diagnosis and management of isolated pituitary metastasis from adenocarcinoma of unknown origin presenting as loss of libido. BMJ Case Rep. 2015;2014-208735. https://doi.org/10.1136/bcr-2014-208735
  35. Gulsin GS, Jocobs ML, Gohil S, Thomas A & Levy M. Competing interests in a lung cancer with metastasis to the pituitary gland: syndrome of inappropriate ADH secretion versus diabetes insipidus. Oxford Medical Case Rep. 2016:125-129.  https://doi.org/10.1093/omcr/omw044
  36. La Rocca G, Mattogno PP, Pompucci A, Coli A, Rigante M, Mangiola A. An extremely rare case of a single isolated pituitary metastasis from hepatocellular carcinoma. Journal of Neurosurg Sciences. 2017;61:213-215.  https://doi.org/10.23736/S0390-5616.16.03252-5
  37. Lim W, Lim D, Chng CL & Lim AY. Thyroid carcinoma with pituitary metastases: 2 case reports and literature review. Case Rep in Endocrinol. 2015;2015:252157. https://doi.org/10.1155/2015/252157
  38. Ikeda H, Yoshimoto T. Clinicopathological study of Rathke’s cleft cysts. Clin Neuropathol. 2002;21(2):82-91. 
  39. Xin W, Rubin MA, McKeever PE. Differential Expression of Cytokeratins 8 and 20 Distinguishes Craniopharyngioma From Rathke Cleft Cyst. Arch Pathol Lab Med. 2002;126(10):1174-1178. https://doi.org/10.5858/2002-126-1174-DEOCAD
  40. Asa SL. Tumor-like lesions of the sella turcica. In: Tumors of the Pituitary Gland. AFIP Atlas of Tumor Pathology Series 4. Washington: American Registry of Pathology; 2011;249-264. 
  41. Güdük M, Aytar MH, Sav A, Berkman Z. Intrasellar arachnoid cyst: A case report and review of the literature. Int J of Surg Case Rep. 2016;23:105-108.  https://doi.org/10.1016/j.ijscr.2016.03.033
  42. Zada G, Lin Ni, Ojerholm E, Ramkissoon Sh, Laws ER. Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships. Review Neurosurg Focus. 2010;28(4):E4.  https://doi.org/10.3171/2010.2
  43. Carmichael JD. Update on the diagnosis and management of hypophysitis. Curr Opin in Endocrinol Diabetes and Obes. 2012;19: 314-321.  https://doi.org/10.1097/MED.0b013e32835430ed.
  44. Mitrofanova LB, Konovalov PV, Ryazanov PA, Raspopova OM, Antonova IV. Primary and secondary hypophysitis: A clinicomorphological study. Arkhiv Patologii. 2016;78(6):43-51. (In Russ.). https://doi.org/10.17116/patol201678643-51
  45. Imber BS, Lee HS, Kunwar S, Blevins LS, Aghi MK. Hypophysitis: a single-center case series. Pituitary. 2015;18:630-641.  https://doi.org/10.1007/s11102-014-0622-5
  46. Faje A. Hypophysitis: Evaluation and Management. Clin Diabetes Endocrinol. 2016; 2:15.  https://doi.org/10.1186/s40842-016-0034-8.
  47. Imga NN, Yildirim AE, Baser OO, Berker D. Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience. Arch Endocrinol Metab. 2019;63:1.  https://doi.org/10.20945/2359-3997000000102.
  48. De Sousa SMC, Earls P, McCormack AI. Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition. Endocrinol Diabetes Metab Case Rep. 2015;2015:150017. https://doi.org/10.1530/EDM-15-0017
  49. Al-Gahtany M, Horvat E, Kovacs K. Pituitary hyperplasia. Hormones. 2003;2(3):149-158. 
  50. Villa C, Lagonigro MS, Magri F, Koziak M, Jaffrain-Rea ML, Brauner R, Bouligand J, Junier MP, Di Rocco F, Sainte-Rose C, Beckers A, Roux FX, Daly AF, Chiovato L. Hyperplasia — adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr Relat Cancer. 2011;18:347-356.  https://doi.org/10.1530/ERC-11-0059

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.